Watch BCLI. Know when insiders buy.
One email the day a filing lands. Free.
BCLI
BRAINSTORM CELL THERAPEUTICS INC.
0.99
−0.06 −5.71%
USD · close Sep 8
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
46
WATCH · shorts 46
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $10.9MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$10.5MNET CASH —52W 0.48 – 1.44SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$3.6M | −$3.9M | — | -0.35 | −$895K | — | — | Aug 14 |
| Q1 2026 · Mar 31 | — | — | — | −$2M | −$2.1M | — | -0.19 | −$1.3M | — | — | Aug 14 |
| Q4 2025 · Dec 31derived | — | — | — | −$2.2M | −$2.4M | — | -0.20 | −$740K | — | — | Mar 31 |
| Q3 2025 · Sep 30 | — | — | — | −$2M | −$2.1M | — | -0.19 | −$1.1M | — | — | Nov 14 |
| Q2 2025 · Jun 30 | — | — | — | −$2.6M | −$2.9M | — | -0.34 | −$3.5M | — | — | Aug 14 |
| Q1 2025 · Mar 31 | — | — | — | −$3.1M | −$2.9M | — | -0.45 | −$1.6M | — | — | Aug 14 |
| Q4 2024 · Dec 31derived | — | — | — | −$3.2M | −$3M | — | -0.51 | −$1M | — | — | Mar 31 |
| Q3 2024 · Sep 30 | — | — | — | −$3M | −$2.7M | — | -0.51 | −$3.3M | — | — | Nov 14 |
| Q2 2024 · Jun 30 | — | — | — | −$3M | −$2.5M | — | -0.60 | −$1.7M | — | — | Nov 14 |
| Q1 2024 · Mar 31 | — | — | — | −$2.5M | −$3.4M | — | -0.75 | −$3.1M | — | — | Nov 14 |
| Q4 2023 · Dec 31derived | — | — | — | −$4.8M | −$5.6M | — | -1.65 | −$3.3M | $0 | −$3.3M | Mar 31 |
| Q3 2023 · Sep 30 | — | — | — | −$6M | −$1.2M | — | -0.45 | −$6.4M | $18K | −$6.4M | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$10M | −$10.3M | — | -1.11 | −$7M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$11.7M | −$11.6M | — | -2.31 | −$9.1M | — | — | — | — |
| FY2023 · to Dec 31 | — | — | −$21.4M | −$17.2M | — | -6.00 | −$20.5M | $18K | −$20.5M | — | — |
| FY2022 · to Dec 31 | — | — | −$24.8M | −$24.3M | — | -0.66 | −$19.3M | $29K | −$19.3M | — | — |
| FY2021 · to Dec 31 | — | — | −$24.5M | −$24.5M | — | -0.68 | −$26.3M | $330K | −$26.6M | — | — |
| FY2020 · to Dec 31 | — | — | −$31.7M | −$31.8M | — | -1.07 | −$35.2M | $378K | −$35.6M | $116K | — |
Every number comes from BRAINSTORM CELL THERAPEUTICS INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.